Ecto-NTPDase-Inhibitors – Inhibitors for use in human therapy

The invention provides a new class of nucleosides

exhibiting a high affinity for individual ecto-nucleotidetriphosphate- diphosphohydrolases (E-NTPDases) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2- receptors (ATP-, ADP-, UTP-, UDP-receptors). Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Future AR/VR controllers could be the palm of your hand

Carnegie Mellon University’s EgoTouch creates simple interfaces for virtual and augmented reality. The new generation of augmented and virtual reality controllers may not just fit in the palm of your…

‘Game changer’ in lithium extraction

Rice researchers develop novel electrochemical reactor. A team of Rice University researchers led by Lisa Biswal and Haotian Wang has developed an innovative electrochemical reactor to extract lithium from natural…

The blue-green sustainable proteins of seaweed

… may soon be on your plate. The protein in sea lettuce, a type of seaweed, is a promising complement to both meat and other current alternative protein sources. Seaweed…